Skip to content

INFECTIOUS DISEASE

LEARN MORE

REsearch summary

VIC seeks to accelerate the efficient & effective early-stage development of new vaccines & immunotherapies for infectious disease.

VIC has been successful in developing novel candidate vaccines and adjuvants for emerging infectious diseases and exploring intriguing aspects of their immunopathogenesis.

To this end current research priorities include:

  • Vaccine development in collaboration with partners worldwide
  • Infection-associated immunopathology
  • Immunotherapy for infectious diseases
  • COVID-19
  • Novel vaccine, therapeutic and diagnostic product research and development

Infectious Disease Pipeline

1 : Initial R&D

2 : Preclinical Efficacy

3 : Preclinical Safety

4 : Initial Human Studies

COVID-19

The Team at VIC rapidly pivoted during a couple of crucial weeks in March 2020 to address clear unmet medical needs for new diagnostics, treatments and a vaccine for SARS-CoV-2. Most importantly, we leveraged our ongoing Department of Defense funded rapid vaccine development platform, VaxCelerate, to target the coronavirus. To this end we partnered with a new biotechnology company, Voltron Therapeutics Inc., to take our new COVID-19 vaccine, called HaloVax, from bench to bedside on an accelerated timeline.
COVID-19

Highlighted Publications

Promiscuous Coxiella burnetii CD4 Epitope Clusters Associated With Human Recall Responses Are Candidates for a Novel T-Cell Targeted Multi-Epitope Q Fever Vaccine.

Front Immunol. 2019 Feb 15;10:207. doi: 10.3389/fimmu.2019.00207. eCollection 2019. PMID: 30828331
Scholzen A, Richard G, Moise L, Baeten LA, Reeves PM, Martin WD, Brauns TA, Boyle CM, Raju Paul S, Bucala R, Bowen RA, Garritsen A, De Groot AS, Sluder AE, Poznansky MC.

A pilot clinical trial of a near-infrared laser vaccine adjuvant: safety, tolerability, and cutaneous immune cell trafficking.

FASEB J. 2019 Feb;33(2):3074-3081. doi: 10.1096/fj.201801095R. Epub 2018 Sep 7. PMID:30192655
Gelfand JA, Nazarian RM, Kashiwagi S, Brauns T, Martin B, Kimizuka Y, Korek S, Botvinick E, Elkins K, Thomas L, Locascio J, Parry B, Kelly KM, Poznansky MC.

explore these labs for more info

POZNANSKY LAB

REEVES LAB

DAI LAB

MUKERJI LAB

GELFAND LAB

RETURN TO VIC TECHNOLOGIES

BACK >